Navigation Links
Warner Chilcott Successfully Completes Refinancing of Senior Secured Credit Facilities and Updates Full Year 2011 Financial Guidance
Date:3/17/2011

able, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness, including increases in the LIBOR rates on our variable-rate indebtedness above the applicable floor amounts; competitive factors in the industry in which we operate, including the approval and introduction of generic or branded products that compete with our products; our ability to protect our intellectual property; a delay in qualifying any of our manufacturing facilities that produce our products or production or regulatory problems with either our own manufacturing facilities or third party manufacturers or API suppliers upon whom we may rely for some of our products; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, and the continued consolidation of the distribution network through which we sell our products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; government regulation, including U.S. and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; adverse outcomes in our outstanding litigation or arbitration matters or an increase in the number of litigation matters to which we are subject; the loss of key senior management or scientific staff; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer ac
'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
2. Warner Chilcott Announces 2011 Financial Guidance Conference Call
3. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
9. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy ... of donor stem cells for dogs with osteoarthritis. Dr. ... has performed clinical stem cell therapy for 7 years. ... if a single injection of donor stem cells into ... pain and inflammation in the treated joints. , ...
(Date:10/19/2014)... October 19, 2014 The Asia-Pacific ... market in Asia-Pacific with analysis and forecast of ... Asia Pacific Bromine Market report, to get an ... provides a glimpse of the segmentation in the ... tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... , , , ... AMLN ) today announced that its Board of Directors has ... , , Mr. Costa was formerly President and ... other executive positions, including Head of the Americas and President and ...
... , ... Latin American-based Investigator Sites Now Available on goBalto.com , ... San Francisco, CA (PRWEB) August 24, 2009 -- ... industry, announced today that Clinical Trials Support is making its proprietary list ...
... , , , ... CTIC) (the "Company") today announced the closing of its previously announced ... Stock and warrants to purchase shares of its common stock in ... has elected to convert all of its shares of Series 2 ...
Cached Biology Technology:Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board 2goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites 2goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites 3Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants 2
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/15/2014)... 15, 2014 Sandata Technologies, LLC, an ... community-based care, today announced it released a case ... Electronic Visit Verification™ Solution (EVV™)  for Quality Care ... health company founded in 1996 and has five ... The study details the challenges facing ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... vegetables in salads are chock-full of important vitamins and ... right type and amount of salad dressing, a Purdue ... fed subjects salads topped off with saturated, monounsaturated and ... of fat-soluble carotenoids ╨ compounds such as lutein, lycopene, ...
... and red wine may enhance exercise training and performance, ... Alberta. Principal investigator Jason Dyck and his team ... natural compound resveratrol improved physical performance, heart function and ... excited when we saw that resveratrol showed results similar ...
... health promotion and lack of success with changing patient ... physical activity counseling in the primary care setting, according ... Public Health, part of The University of Texas Health ... barriers must be addressed in order to incorporate counseling ...
Cached Biology News:Study: No-fat, low-fat dressings don't get most nutrients out of salads 2UTHealth study addresses barriers to physical activity counseling 2UTHealth study addresses barriers to physical activity counseling 3
... kit is for fine-tuning the bombardment conditions ... is recommended when you are first using ... includes 0.25 g each of 0.6 micrometer, ... microcarriers, 100 each of 9 rupture disks, ...
... Tecans fully automated solution for cell ... automation for cell-line maintenance, expansion, harvesting ... system built upon standard, industry proven ... handling configuration capable of both rapid ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... sequencing is the experimental process of determining ... The automated DNA Sequencing is based on ... polymerase, which allows cycle sequencing reactions. The ... in a capillary instrument controlled by a ...
Biology Products: